15 patients with primitive carcinoma in situ of the bladder were administered 50 mg/week of Epirubicin; 14 responded to this control therapy with negative urinary cytology and biopsies within an average of 25.6 months. After an average follow up of 47.7 months, 8 out of the 15 patients are still in a state of complete remission, 1 has a recurrent grade 3 carcinoma, 5 are in progression (3 T1 and 2 T2) and 1 has a grade 2 Ta recurrence. 3 patients died from the disease.
FarrowG.M.BarleboH.EnjojiM.: Transitional cell carcinoma in situ: Progress in clinical and biological research. Vol. 221, 85–896, 1986.
2.
Second International Consensus Development Conference on Guidelines for clinical Research in Bladder Cancer. Hakone, Japan, 28–30 settembre 1987.
3.
MelamedM.R.VoutsaM.G.GrabstaldH.: Natural history and clinical behaviour of in situ carcinoma of the human urinary bladder. Cancer17: 1533–1545, 1964.
4.
FarrowG.M.UtzD.C.RifeC.C.GreenL.F.: Clinical observations on 69 cases of in situ carcinoma of the urinary bladder. Cancer res.37: 2794–2798, 1977.
5.
KossL.G.: Mapping of the urinary bladder: its impact on the concepts of bladder cancer. Hum. Pathol.10: 553–4, 1979.
6.
KossL.G.MelamedM.R.KellyR.E.: Further citology and histologic studies of bladder lesions in workers exposed to para-aminophenyl: progress report. J. Natl. cancer Inst.43: 233–234, 1969.
7.
KurthK.H.MrossK.TenkateF.: Phase I/O study of intravesical epirubicin in patients with carcinoma in situ of the bladder. Prog. Clin. Biol. Res.350: 41–59, 1990.
8.
FarrowG.M.UtzD.C.RifeC.C.Morphological and clinical observations of patients with early bladder cancer treated with total cystectomy. Cancer Res.36: 2495–2501, 1976.
9.
SolowayM.S.FordK.S.: Subsequent tumor analysis of 36 patients who have received intravesical Mitomycin C for superficial bladder cancer. J. Urol.130: 74–78, 1983.
10.
OrihuelaE.HerrH.W.PinskiC.M.WithmoreW.F.Jr.: Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer60: 326–333, 1987.
11.
StegA.LeleuC.Boccon GibodL.DebreB.: Traitement des tumeurs superficielles de vessie par BCG-therapie intra-vesicale, in: International Workshop in urology, 203–212, 1988, Acta Medica, Roma.
12.
GlashamR.W.: A randomized controlled study of intravesical alpha-2B-interferon in carcinoma in situ of the bladder. J. Urol.144: 658–661, 1990.
